Research
We strive to uncover the underlying causes of treatment failure in specific patient subgroups and to develop innovative, personlized therapeutic strategies that translate scientific discovery into meaningful clinical benefit.
Immuno-Oncology
Our laboratory aims to realize personalized medicine by performing integrative analyses of multi-omics databases from non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors, including WES, WTS, WGS, single-cell, and spatial transcriptomics data.
Building upon these comprehensive databases, we investigate the molecular and immunological mechanisms underlying therapeutic response and resistance to immunotherapy.
In parallel, we perform liquid biopsy-based analyses, including cell-free DNA and blood immune profiling, to identify biomarkers for molecular residual disease (MRD) detection and predict treatment response and resistance.
Our laboratory is dedicated to advancing the understanding and treatment of EGFR-mutant non-small cell lung cancer (NSCLC) by translating molecular and immunologic insights into clinical applications.
Leveraging one of the world's largest patient cohorts, we integrate multi-omics and clinical data to investigate tumor evolution, therapeutic resistance, and treatment response in real-world settings.
Through this integrative and translational approach, we aim to bridge fundamental biology with clinical innovation, ultimately developing more precise and durable therapeutic strategies for patients with EGFR-mutant NSCLC.
Targeted Therapy
Small-Cell Lung Cancer (SCLC)
Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma characterized by rapid relapse and the development of resistance despite initial chemosensitivity. In contrast to non–small cell lung cancer (NSCLC), therapeutic progress in SCLC has remained limited for decades, with recent advances largely driven by the emergence of immunotherapy and targeted therapy.
Our laboratory leverages one of the world's largest clinically and molecularly annotated SCLC cohorts, encompassing extensive collections of tumor tissues, blood samples, and next-generation sequencing (NGS) data.
Through these integrative analyses, we aim to define the molecular and immune landscape of SCLC, identify novel biomarkers of treatment response, and ultimately advance precision therapeutic strategies for patients with SCLC.